Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. 2016;5:155–71. https://doi.org/10.21037/tlcr.2016.02.02

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bondarev AD, Attwood MM, Jonsson J, Chub-arev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87:4577–97. https://doi.org/10.1111/bcp.14889

Article  PubMed  Google Scholar 

Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504–22. https://doi.org/10.1016/j.lfs.2021.119504

Article  CAS  PubMed  Google Scholar 

Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed and Biotechnol. 2011;2011:1–10. https://doi.org/10.1155/2011/371832

Article  CAS  Google Scholar 

Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y, Fei X, et al. HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem. 2024;265:116129–45. https://doi.org/10.1016/j.ejmech.2024.116129

Article  CAS  PubMed  Google Scholar 

Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 2009;280:134–44. https://doi.org/10.1016/j.canlet.2009.02.027

Article  CAS  PubMed  Google Scholar 

Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer D-rugs. Int J Mol Sci. 2017;18:1414–38. https://doi.org/10.3390/ijms18071414

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shetty MG, Pai P, Deaver RE, Satyamoorthy K, Babitha KS. Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res. 2021;170:105695–7. https://doi.org/10.1016/j.phrs.2021.105695

Article  CAS  PubMed  Google Scholar 

Sangwan R, Rajan R, Mandal PK. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. Eur J Med Chem. 2018;158:620–706. https://doi.org/10.1016/j.ejmech.2018.08.073

Article  CAS  PubMed  Google Scholar 

Yuan H, Marmorstein R. Structural basis for sirtuin activity and inhibition. J Biolog Chem. 2012;287:42428–35. https://doi.org/10.1074/jbc.R112.372300

Article  CAS  Google Scholar 

Smalley JP, Baker IM, Pytel WA, Lin L-Y, Bowman KJ, Schwabe JWR, et al. Optimization of class I histone deacetylase PROTACs reveals that HDAC1/2 degradation is critical to induce apoptosis and cell arrest in cancer cells. J Med Chem. 2022;65:5642–59. https://doi.org/10.1021/acs.jmedchem.1c02179

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schübeler D, Hess L, Moos V, Lauber AA, Reiter W, Schuster M, et al. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation. PLOS Genet. 2022;18:1010376–92. https://doi.org/10.1371/journal.pgen.1010376

Article  CAS  Google Scholar 

Li J, Lu L, Liu L, Ren X, Chen J, Yin X, et al. HDAC1/2/3 are major histone desuccinylases critical for promoter desuccinylation. Cell Discov. 2023;9:85–101. https://doi.org/10.1038/s41421-023-00573-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. 2011;2011:1–12. https://doi.org/10.1155/2011/475641

Article  CAS  Google Scholar 

Guerrant W, Mwakwari SC, Chen PC, Khan SI, Tekwani BL, Oyelere AKJC. A structure–activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors. 2010;5:1232-5. https://doi.org/10.1002/cmdc.201000087.

Cheshmazar N, Hamzeh-Mivehroud M, Nozad Charoudeh H, Hemmati S, Melesina J, Dastmal-chi S. Current trends in development of HDAC-based chemotherapeutics. Life Sci. 2022;308. https://doi.org/10.1016/j.lfs.2022.120946.

Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84–90. https://doi.org/10.1038/nbt1272

Article  CAS  PubMed  Google Scholar 

Sawas A, Radeski D, O’Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6:202–8. https://doi.org/10.1177/2040620715592567

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma S, Bailey H, Stenehjem D. Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015;6:269–76. https://doi.org/10.2147/jbm.S69140

Article  PubMed  PubMed Central  Google Scholar 

Reddy SA. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Crit Rev Oncol Hematol. 2016;106:99–107. https://doi.org/10.1016/j.critrevonc.2016.07.001

Article  PubMed  Google Scholar 

Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2011;69:901–9. https://doi.org/10.1007/s00280-011-1766-x

Article  CAS  PubMed  Google Scholar 

Han H, Feng X, He T, Wu Y, He T, Yue Z, et al. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor. Chem Biol Drug Des. 2023;103:14366–84. https://doi.org/10.1111/cbdd.14366

Article  CAS  Google Scholar 

Yu F, Ran J, Zhou J. Ciliopathies: does HDAC6 represent a new therapeutic target? Trends Pharmacol Sci. 2016;37:114–9. https://doi.org/10.1016/j.tips.2015.11.002

Article  CAS  PubMed  Google Scholar 

San JE, Gimenez C, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019;11:1794–17. https://doi.org/10.3390/cancers11111794

Article  CAS  Google Scholar 

Thomas M, Clarhaut J, Tranoy-Opalinski I, Gesson JP, Roche J, Papot S. Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. Bioorg Med Chem. 2008;16:8109–16. https://doi.org/10.1016/j.bmc.2008.07.048

Article  CAS  PubMed  Google Scholar 

Jespersen H, Olofsson Bagge R, Ullenhag G, Carneiro A, Helgadottir H, Ljuslinder I, et al. Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study). Ann Oncol. 2019;19:415–21. https://doi.org/10.1093/annonc/mdz394.068

Article  CAS  Google Scholar 

Huang R, Zhang X, Min Z, Shadia AS, Yang S, Liu X. MGCD0103 induces apoptosis and simultaneously increases the expression of NF‑κB and PD‑L1 in classical Hodgkin’s lymphoma. Exp Ther Med. 2018;16:3827–34. https://doi.org/10.3892/etm.2018.6677

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakagawa-Saito Y, Saitoh S, Mitobe Y, Sugai A, Togashi K, Suzuki S, et al. HDAC Class I inhibitor domatinostat preferentially targets glioma stem cells over their differentiated progeny. Int J Mol Sci. 2022;23:8084–95. https://doi.org/10.3390/ijms23158084

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shinke G, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, et al. Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer. Cancer Sci. 2018;109:2520–31. https://doi.org/10.1111/cas.13700

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang RH, Guo HY, Deng H, Li J, Quan ZS. Piperazine skeleton in the structural modification of natural products: a review. J Enzyme Inhib Med Chem. 2021;36:1165–97. https://doi.org/10.1080/14756366.2021.1931861

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatnapure GD, Keche AP, Rodge AH, Birajd-ar SS, Tale RH, Kamble VM. Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antimicrobial agent. Bioorg Med Chem Lett. 2012;22:6385–90. https://doi.org/10.1016/j.bmcl.2012.08.071

Article  CAS  PubMed  Google Scholar 

Li R, Wu J, He Y, Hai L, Wu Y. Synthesis and in vitro evaluation of 12-(substituted aminomethyl) berberrubine derivatives as anti-diabetics. Bioorg Med Chem Lett. 2014;24:1762–5. https://doi.org/10.1016/j.bmcl.2014.02.032

Article  CAS  PubMed  Google Scholar 

Cao F, Zwinderman MRH, van Merkerk R, Ettema PE, Quax WJ, Dekker FJ. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages. Eur J Med Chem. 2019;177:457–66. https://doi.org/10.1016/j.ejmech.2019.05.038

Article  CAS  PubMed  Google Scholar 

Ruzic D, Ellinger B, Djokovic N, Santibanez JF, Gul S, Beljkas M, et al. Discovery of 1-Benzhydryl-Piperazine-Based HDAC inhibitors with anti-breast cancer activity: synthesis, molecular modeling, in vitro and in vivo biological evaluation. Pharmaceutics. 2022;14:2600–22. https://doi.org/10.3390/pharmaceutics14122600

Article  CAS  PubMed  PubMed Central